- Facing pharmacy trends for the remainder of the year
- FDA approves Plan B One-Step OTC switch
- Senate passes Drug Quality and Security Act
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
ST. LOUIS — K-V Pharmaceutical announced Wednesday that the Food and Drug Administration extended its Prescription Drug User Fee Act action date to April 13 for a drug under development for preventing preterm birth.
K-V, which acquired the injected drug Gestiva (hydroxyprogesterone caproate) from Hologic in 2008, said Hologic originally had been told the FDA would take action Thursday.
K-V said it was confident the drug would receive approval and that the FDA would take action on or before the new PDUFA date.